Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia | recruiting | Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT04544592 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | recruiting | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05707273 | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT07153796 | A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma | not yet recruiting | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02146924 | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 71 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05397496 | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | active not recruiting | Phase 1 | 61 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 28, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | recruiting | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT03241940 | Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 33 | Stanford UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 30 | Liping DouOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07040982 | Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07575919 | Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL | recruiting | Phase 1 / Phase 2 | 20 | Liping DouOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01860937 | T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) | not yet recruiting | Phase 1 | 26 | Wake Forest University Health SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05157971 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | recruiting | Phase 1 / Phase 2 | 115 | Stephan Grupp MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06777979 | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06879340 | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 54 | University of Kansas Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | active not recruiting | Phase 1 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors | not yet recruiting | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06880913 | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06326008 | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial | recruiting | Phase 1 | 48 | Beijing GoBroad HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | recruiting | Phase 1 | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06287528 | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06580301 | Study of YK012 in B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 46 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05366218 | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia(Anti-CD19-ALL) | recruiting | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06080191 | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | recruiting | Phase 1 | 24 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials